| 臺大學術典藏 |
2022-07-12T05:28:49Z |
Assessment of ketamine uropathy
|
Yang S.S.; Wu C.-H.; Chen J.Y.J.; SHANG-JEN CHANG; Jang M.Y.; Wu W.J.; Ruan Y.S.; Li S.Y.; Wu J.S.; Chung Y.C.; Li W.J.; Li Y.H.; Tang Y.C.; Shen K.H.; Lin W.Y.; Chen J.S.; Lee M.H.; Chen M.H.; Zou J.L.; Jhang J.S.; Syu J.S.; Chang S.J.; Lin A.T.L.; Fan Y.H.; Meng E.; Syu Y.J.; Yu H.J.; Guo Y.C.; Ye J.S.; Wang Y.J.; Jhang J.F.; Jiang Y.H.; Kuo H.C.; Team for National Registration of Ketamine Uropathy |
| 臺大學術典藏 |
2021-03-03T03:01:17Z |
Folic acid prevents neural tube defects: International comparison of awareness among obstetricians/gynecologists and urologists
|
Kondo A.;Kamihira O.;Gotoh M.;Ozawa H.;Lee T.Y.;Lin A.T.-L.;Kim S.-R.;Ho-Hsiung Lin; Kondo A.; Kamihira O.; Gotoh M.; Ozawa H.; Lee T.Y.; Lin A.T.-L.; Kim S.-R.; HO-HSIUNG LIN |
| 臺大學術典藏 |
2021-03-03T03:00:57Z |
Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010
|
Kuo H.-C.; HO-HSIUNG LIN; Yu H.-J.; Cheng C.-L.; Hung M.-J.; Lin A.T.L.; Chang C.-H.; Chuang Y.-C.; Cha T.-L.; Chen G.-D.; Chen C.-S.; Wu M.-P.; Wu T.-L.; Yu K.-J.; Huang S.-T.; The Taiwan Mirabegron Study Team |
| 臺大學術典藏 |
2021-03-03T03:00:57Z |
Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
|
Kuo H.-C.; HO-HSIUNG LIN; Yu H.-J.; Cheng C.-L.; Hung M.-J.; Lin A.T.L. |
| 臺大學術典藏 |
2021-02-02T00:43:13Z |
Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
|
Hong-Jeng Yu;Lin A.T.-L.;Yang S.S.-D.;Tsui K.-H.;Wu H.-C.;Cheng C.-L.;Cheng H.-L.;Wu T.T.;Chiang P.-H.; HONG-JENG YU; Lin A.T.-L.; Yang S.S.-D.; Tsui K.-H.; Wu H.-C.; Cheng C.-L.; Cheng H.-L.; Wu T.T.; Chiang P.-H. |
| 臺大學術典藏 |
2021-02-02T00:43:02Z |
Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010
|
Kuo H.-C.; Lin H.-H.; HONG-JENG YU; Cheng C.-L.; Hung M.-J.; Lin A.T.L.; Chang C.-H.; Chuang Y.-C.; Cha T.-L.; Chen G.-D.; Chen C.-S.; Wu M.-P.; Wu T.-L.; Yu K.-J.; Huang S.-T.; The Taiwan Mirabegron Study Team |
| 臺大學術典藏 |
2021-02-02T00:43:02Z |
Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
|
Kuo H.-C.;Lin H.-H.;Hong-Jeng Yu;Cheng C.-L.;Hung M.-J.;Lin A.T.L.; Kuo H.-C.; Lin H.-H.; HONG-JENG YU; Cheng C.-L.; Hung M.-J.; Lin A.T.L. |
| 臺大學術典藏 |
2021-02-02T00:43:01Z |
Assessment of ketamine uropathy
|
Yang S.S.;Wu C.-H.;Chen J.Y.J.;Chang S.-J.;Jang M.Y.;Wu W.J.;Ruan Y.S.;Li S.Y.;Wu J.S.;Chung Y.C.;Li W.J.;Li Y.H.;Tang Y.C.;Shen K.H.;Lin W.Y.;Chen J.S.;Lee M.H.;Chen M.H.;Zou J.L.;Jhang J.S.;Syu J.S.;Yang S.S.;Chang S.J.;Lin A.T.L.;Fan Y.H.;Meng E.;Syu Y.J.;Hong-Jeng Yu;Guo Y.C.;Ye J.S.;Wang Y.J.;Jhang J.F.;Jiang Y.H.;Kuo H.C.;Team For National Registration Of Ketamine Uropathy; Yang S.S.; Wu C.-H.; Chen J.Y.J.; Chang S.-J.; Jang M.Y.; Wu W.J.; Ruan Y.S.; Li S.Y.; Wu J.S.; Chung Y.C.; Li W.J.; Li Y.H.; Tang Y.C.; Shen K.H.; Lin W.Y.; Chen J.S.; Lee M.H.; Chen M.H.; Zou J.L.; Jhang J.S.; Syu J.S.; Yang S.S.; Chang S.J.; Lin A.T.L.; Fan Y.H.; Meng E.; Syu Y.J.; HONG-JENG YU; Guo Y.C.; Ye J.S.; Wang Y.J.; Jhang J.F.; Jiang Y.H.; Kuo H.C.; Team for National Registration of Ketamine Uropathy |
| 臺大學術典藏 |
2020-02-17T08:51:04Z |
Folic acid prevents neural tube defects: International comparison of awareness among obstetricians/gynecologists and urologists
|
Kondo A; Kamihira O; Gotoh M; Ozawa H; Lee T.Y; Lin A.T.-L; Kim S.-R; HO-HSIUNG LIN |
| 臺大學術典藏 |
2020-02-17T08:50:53Z |
Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010
|
Kuo H.-C; HO-HSIUNG LIN; Yu H.-J; Cheng C.-L; Hung M.-J; Lin A.T.L; Chang C.-H; Chuang Y.-C; Cha T.-L; Chen G.-D; Chen C.-S; Wu M.-P; Wu T.-L; Yu K.-J; Huang S.-T; The Taiwan Mirabegron Study Team |
| 臺大學術典藏 |
2020-02-17T08:50:53Z |
Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
|
Lin A.T.L.; Hung M.-J; Cheng C.-L; Kuo H.-C; HO-HSIUNG LIN; Yu H.-J |
